Pharmaceutical Executive
One of the Hatch-Waxman Act's authors opposes proposed changes to the 1984 legislation.
One of the Hatch-Waxman Act's authors opposes proposed changes to the 1984 legislation. At a Senate hearing last month, Senator Orrin Hatch (R, Utah) said he disagrees with proposals to eliminate the 30-month "stay" on FDA approval of contested generic products or to revise the 180-day exclusivity period for new generics. Those provisions are key elements of a bill sponsored by Senators Charles Schumer (D, New York) and John McCain (R, Arizona) that aims to end tactics allegedly used by innovator companies to delay generic competition.
However, Representative Henry Waxman (D, California) indicated that he may not agree with Hatch. Such abuses of the system by brand-name companies have upset the "appropriate balance" established in the original bill, Waxman states in a letter to the Senate Health, Education, Labor and Pensions (HELP) Committee.
Hatch says Congress must go slow in determining "how to restore that balance." At the HELP panel hearing chaired by Senator Ted Kennedy (D, Massachusetts), Schumer blasted brand-name companies for filing weak or invalid patents and for making anticompetitive deals designed to extend monopolies. The main charge is that innovators file late patents on minor innovations, such as new dosing methods, largely to keep generics off the market.
Industry lawyers counter that such patents seldom prevent generic competitors from making original products, just from making the new formulations. The charges and countercharges have generated a good deal of skepticism about all claims in the debate.
Hatch's call for Congress to get the facts before changing the law is likely to carry the day. Hatch suggests other possible changes to the generics bill, such as dropping the 180-day exclusivity policy and linking elimination of the 30-month stay with that of the Bolar amendment, which permits generics makers to access innovators' data before patent expiration. Hatch wants hard information about the occurance of multiple consecutive 30-month stays and about the frequency of suits that challenge later-issued patents.
The Federal Trade Commission is expected to issue a report on those issues this summer. One question is whether Hatch-Waxman should be revised to include generic biologicals, a move opposed by innovator companies. Despite Hatch's call for proceeding thoughtfully, sponsors of McCain-Schumer are promoting the bill as a way to reduce expenditures for prescription therapies. This fall, members of Congress may jump on the generic reform bandwagon as an easy way to do "something" about soaring medical costs.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
2 Commerce Drive
Cranbury, NJ 08512